GB Sciences Inc (OTCMKTS:GBLX) To Conduct Cannabis Use And Awareness Seminars

GB Sciences Inc (OTCMKTS:GBLX) says it will unveil some new medical cannabis products in a matter of months. This business guru believes it is good to educate Louisiana pharmacists and physicians about the products. The company’s subsidiary GB Sciences Louisiana is making preparations to conduct educative seminars starting August. It will cooperate with the LSU AgCenter and several state-approved medical cannabis pharmacies in conducting the sessions.

The program

Louisiana’s medical cannabis program seeks to encourage more active participation of the pharmacists and physicians in the program. Those that have a direct touch with cannabis patients at the point of sale will find the program quite useful.

 The number of patients in need of cannabis products continues to rise with time because of the associated benefits. These patients will need to make a lot of consultations in order to understand the product better. The participating parties will be prepared adequately to answer all questions that might arise.

The President of GB Sciences Louisiana John Davis opines, “We want to help healthcare professionals understand the potency of our formulations, how to best recommend our products and the evidence-based approach that influenced and supports their design and use.”

Dr. Andrea’s thoughts

The Director of GB Sciences who is also its Chief Science Officer Dr. Andrea Small-Howard has spoken about the matter. He reveals that they will make presentations of the placebo-controlled human clinical trial data in a random way. The target will be to make an illustration of the safety of the products. Asides from that, they will also be about illustrating the medical cannabis-based therapies potential efficacy. Experts say that the products will have to adhere to the approved medical conditions in the state of Louisiana.

Tutorials will also focus on showcasing the recommended dosage and usage of new medical cannabis products. Dr. Small-Howard advises cannabis patients to start by taking low doses of the products initially. As time progresses, they will be free to increase the dose in bits until they achieve the desired level of relief. The official says that they will be welcoming more personalized approaches towards helping patients in need. According to him, the ingredients in the products have different effects on different patients.


GB Sciences Inc (OTCMKTS:GBLX) Submits Its Patent Application For Cannabis-Based Chronic Pain Treatments

GB Sciences Inc (OTCMKTS:GBLX) announced on Wednesday that its subsidiary GBS Global Biopharma, Inc. filed a patent application for its chronic pain formulations made using cannabis extracts.

The newly filed patent covers the proprietary cannabis-based formulations that are designed using functional assay data and molecular docking simulations. A lot of research and development is currently being poured into the pursuit of new pain treatments which might help curb opioids addiction and opioid-related deaths. 

Opioids are currently used to treat chronic pain but their major disadvantage is that they are highly addictive. More than 1.7 Million Americans are affected by opioid addiction and about 50,000 people die annually from opioid-related causes such as overdose. GB Sciences’ new patent for cannabis-based chronic pain treatment presents a chance to reduce and possibly eliminate the need for opioids.

“Unlike others who are narrowly focused on using a very limited number of cannabinoids for the treatment of pain, we embraced the complexity of whole-plant cannabis extracts,” stated Dr. Andrea Small-Howard, the Chief Science Officer at GBS.

GB Sciences’ patent promises to deliver pain relief alternatives without toxicity drawbacks

Dr. Andrea also noted that GBS developed complex combinations of TRP ligands that are based on Cannabis and can desensitize numerous TRP channels at the same time. The complex compounds are also designed to perform effectively while at the same time avoiding the numbness and neural toxicity that results from capsaicin-based pain relievers applied topically.

GBS has been working on the project together with its research partners from Chaminade University. They are the first to model the cannabidiol and myrcene putative TRPV1-binding sites. Cannabidiol and Myrcene are among the active ingredients that GBS includes in the chronic pain-targeting complex mixtures.

The development team also leveraged the information that they secured from the TRPV1-binding pockets to identify the pain-relieving advantages of the compounds. GB Sciences is one of the companies that have been carrying out cannabis-related research to solve some of the common health conditions. The recently filed patent therefore represents significant progress not only for the company but also for the cannabis industry and also the health sector.


GB Sciences Inc (OTCMKTS:GBLX) Associates With Cura Cannabis Solutions

In the last trading session, the stock price of GB Sciences Inc (OTCMKTS:GBLX) gained more than 22% to close the day at $0.8003. Among other updates, back in the month of October, the company reported that it has finalized a production deal with Cura Cannabis Solutions to produce premium quality cannabis oils and associated products using the company’s production license managed by its Cultivation Labs™.

The details

Currently the leading cannabis oil firm in Oregon with operations up and ongoing in Nevada and California, Cura Cannabis is the major provider of premium hemp oil and cannabis oil to the legal international and domestic markets, and is widely renowned in the industry for the product quality. The firm is famous for its Select CBD and Select Oil brands, providing different products that reach cannabis customers of all experience levels.

Cura Cannabis estimates oil sales and production in Nevada to be around 250,000 grams of oil a month at the outset, surging to around 500,000 grams a month over the imminent term. Nitin Khanna, the CEO of Cura Cannabis, reported that scale, deep domain expertise and quality are three major elements that goes into the success of their firm, and this association with GB Sciences exhibits a deal between two companies which are well positioned for what’s ahead in the buzzing regulated cannabis market. The CEO added that they look forward to associating together to advance premium products for Nevada. They have interesting plans for the future.

This production deal guarantees GB Sciences a fixed royalty on every gram yielded and offered under the deal, an enterprise which will offer company with a growing and significant monthly cash flow. The deal with Cura Cannabis also firmly institutes GB Sciences as a leading vertically integrated cannabis firm, adding oil production to its tissue propagation, distribution and cultivation capabilities.

Marijuana Science

Growblox Sciences Inc (OTCMKTS:GBLX) Files Cannabis-Based Formulation Patent Applications

Growblox Sciences Inc (OTCMKTS:GBLX) has recently filed multiple patent applications for the innovations developed by Growblox Life Sciences, LLC.

Patent Applications

The company’s patent applications include complex-cannabinoid (CBD)-containing substances that can improve dopamine secretion and neuronal protection from mitochondrial-induced free radical damage, which happens during the disease progression of patients suffering from Alzheimer’s disease (AD), Huntington’s disease, Lewy Body Dementia (LBD), Parkinson’s disease, among others. According to the World Health Organization (WHO), the neurodegeneration linked to these conditions is rapidly growing especially among the elderly.

“Unlike many other companies and researchers who try to reduce the natural complexity in the cannabis plant, we embrace it and it informs our therapeutic mixtures,” boasted Andrea Small-Howard, Ph.D., Growblox Sciences Chief Science Officer (CSO), about the company’s efforts involving cannabis-based mixtures since 2014.

Small-Howard has also taken pride in diverse human cannabis receptors being included in the formulations being developed by Growblox Sciences. Most companies only test CB1 and CB2 receptors.

With its current patent application, Growblox Sciences expect to become a key player in the pharmaceutical industry for neurological diseases in the US, which can potentially become about a $129-billion industry by 2020.

Treating Parkinson’s Disease

These dedicated initiatives are geared towards coming up with efficient treatment options for a variety of diseases.

Accordingly, Growblox Sciences will begin with Parkinson’s disease given the heightened demand for an effective treatment option. Eventually, as per John Poss, Growblox Sciences CEO, the company will focus on other conditions in the coming months.

Amid the regulatory challenges awaiting these advancements, the company is nonetheless hopeful about the dramatic revenue growth this opportunity brings in the next five years.

Annual Meeting of Shareholders

In other news, Growblox Sciences has held the Annual Meeting of Shareholders in October.

Voting shareholders have approved the appointment of Craig Ellins and Small-Howard as directors serving a two-year term each; the appointment of Leslie Bocskor, Poss, and Shane Terry as directors serving a three-year term each; the appointment of Patrick Heyn, CPA, as Growblox Sciences Auditor; and the modification of articles of incorporation, reducing the number authorized common shares to 200 million from 250 million and creating 50 million preferred shares.


Growblox Sciences Inc (OTCMKTS:GBLX) Reports Patent Application For Cure Of Different Diseases

Growblox Sciences Inc (OTCMKTS:GBLX) announced the submission of the first of several patent filings for life science inventions by its subsidiary firm, Growblox Life Sciences, LLC.  The existing provisional patent application comprises complex-cannabinoid-containing mixtures efficient of enhancing dopamine secretion and safeguard neurons from the mitochondrial-induced unrestricted radical damage that happens during disease development in the brains of people suffering with Parkinson’s disease, Lewy Body Dementia, Huntington’s disease and Alzheimer’s disease, among others.

The highlights

For the past two years, Growblox Sciences has been working towards the development of novel, patentable cannabis-based medicines under the supervision of Dr. Andrea Small-Howard, who is the Chief Science Officer of company. The CSO said that this patent filing is the first in a series that were developed based on their unique novel approach to advancing cannabis-based treatments.

Unlike many other researchers and companies who try to minimize the natural complication in the cannabis crop, they embrace it and it apprises their therapeutic mixtures. Additionally, the company assesses its mixtures in disease systems that comprise a natural diversity of cannabis-receptors, not just CB2 and CB1 receptors, which are the receptors assessed by many pioneering cannabinoid researchers.

The efficient and fast screening system then assesses the efficiency of the cannabis-based mixtures comprising dozens of individually acting mediators in order to make active treatments for different diseases. They plan to start with Parkinson’s disease as these patients are in need of an effective therapeutic cure. The additional benefit is that Parkinson’s treatment does not comprise substantial quantity of the psychoactive compound, “delta-9 tetrahydrocannabinol.”

John Poss, the CEO of Growblox Sciences, reported that their objective is to help the nearly 1 million patients in the U.S. and 10 million world-wide that are suffering with Parkinson’s disease via their life science research. They expect being able to utilize the same research procedures to create additional innovative therapeutic alternatives for other underserved subject groups in the imminent months.

Pin It on Pinterest